Treatment of dilated cardiomyopathy with carvedilol in children

Turkish Journal of Pediatrics

Volumn 51, Issue 4, 2009, Pages 354-360

  Erdoǧan, Ilkay ^a   Özer, Sema ^a   Karagöz, Tevfik ^a   Çeliker, Alpay ^a   Özkutlu, Süheyla ^a   Alehan, Dursun ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Beta blocker; Carvedilol; Dilated cardiomyopathy; Heart failure; Treatment

Indexed keywords

ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN;

ADOLESCENT; ARTICLE; CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; INFANT; MALE; PEDIATRICS; PRESCHOOL CHILD; SCHOOL CHILD; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PROPANOLAMINES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 70649100109     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138: 505-511. (Pubitemid 32319723)
2. Blume ED, Canter CE, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27: 336-342. (Pubitemid 43828673)
3. Reithmann C, Reber D, Kozlik-Feldmann R. A postreceptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Eur J Pharmacol 1997; 330: 79-86. (Pubitemid 27304036)
4. Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916-922. (Pubitemid 34595354)
5. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol 2005; 21: 344-348. (Pubitemid 40662881)
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
7. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-2806. (Pubitemid 26411744)
8. Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999; 18: 269-274.
9. Spicer RL. Carvedilol - a new dimension in pediatric heart failure therapy. J Pediatr 2001; 138: 457-458. (Pubitemid 32319714)
10. Ross RD. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13: 72-75.
11. Gachara N, Prabhakaran S, Srinivas S, Farzana F, Krishnan U, Shah MJ. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report. Indian Heart J 2001; 53: 74-78. (Pubitemid 32591409)
12. Laer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916-922. (Pubitemid 34595354)
13. Aiba T, Ishida K, Yoshinaga M, Okuno M, Hashimoto Y. Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. Biol Pharm Bull 2005; 28: 114-119. (Pubitemid 40879794)
14. Ratnapalan S, Griffiths K, Costei AM, Benson L, Koren G. Digoxin-carvedilol interactions in children. J Pediatr 2003; 142: 572-574.
15. Frantz RP, Olson LJ, Grill D, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005; 149: 541-547. (Pubitemid 40585419)
16. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436-442. (Pubitemid 32721772)
17. Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004; 94: 448-453. (Pubitemid 39127468)
18. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 40: 2034-2038. (Pubitemid 35425373)
19. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in children with cardiomyopathy: 3- year experience at a single institution. J Heart Lung Transplant 2004; 23: 832-838. (Pubitemid 38953866)
20. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002; 185: 218-227. (Pubitemid 36062795)